documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
59 rows where docket_id = "FDA-2015-D-1211" and posted_year = 2023 sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, comment_start_date, open_for_comment, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2015-D-1211-0368 | FDA | None FDA-2015-D-1211 | Reference 7 Van de perre p re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:33Z | 0 | 0 | 09000064859fc420 | |||
| FDA-2015-D-1211-0397 | FDA | None FDA-2015-D-1211 | Reference 36_FAIR_Conclusions from the For the Assessment of Individualized Risk (FAIR) group re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:55Z | 0 | 0 | 09000064859fd93c | |||
| FDA-2015-D-1211-0402 | FDA | None FDA-2015-D-1211 | Reference 41_Blood safety implications of donors using HIV preexposure prophylaxis re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:59Z | 0 | 0 | 09000064859fd941 | |||
| FDA-2015-D-1211-0394 | FDA | None FDA-2015-D-1211 | Reference 33- O Brien - Donor screening question alternatives to men who have sex with men time deferral Potential (1) re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:52Z | 0 | 0 | 09000064859fd865 | |||
| FDA-2015-D-1211-0403 | FDA | None FDA-2015-D-1211 | Reference 42_AABB_Updated Recommendations on Donor Deferral for Use of Antiretroviral Medications for HIV Prevention and Treatment re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:08:00Z | 0 | 0 | 09000064859fd942 | |||
| FDA-2015-D-1211-0362 | FDA | None FDA-2015-D-1211 | Reference 1 REV. Epstein_et_al-2013-Transfusion re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:29Z | 0 | 0 | 09000064859fbfcf | |||
| FDA-2015-D-1211-0370 | FDA | None FDA-2015-D-1211 | Reference 9 HIV and the blood supply re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:35Z | 0 | 0 | 09000064859fc422 | |||
| FDA-2015-D-1211-0390 | FDA | None FDA-2015-D-1211 | Reference 29 REV. Custer - Transfusion-transmissible infection re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:50Z | 0 | 0 | 09000064859fd861 | |||
| FDA-2015-D-1211-0360 | FDA | None FDA-2015-D-1211 | Recommendations for Evaluating Donor Eligibility Using Individual Risk- Based Questions To Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Guidance for Industry; Availability | Notice | Notice of Availability | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T04:00:00Z | 2023-05-12T12:59:32Z | 2023-10252 | 0 | 0 | 09000064859fa444 | |
| FDA-2015-D-1211-0387 | FDA | None FDA-2015-D-1211 | Reference 26 Offergeld2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:48Z | 0 | 0 | 09000064859fd85e | |||
| FDA-2015-D-1211-0363 | FDA | None FDA-2015-D-1211 | Reference 2 Stramer_et_al-2013-Transfusion re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:30Z | 0 | 0 | 09000064859fbfd0 | |||
| FDA-2015-D-1211-0371 | FDA | None FDA-2015-D-1211 | Reference 10 Current Trends Prevention of Acquired Immune Deficiency Syndrome (AIDS)_ Report of Inter-Agency Recommendations re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:35Z | 0 | 0 | 09000064859fc423 | |||
| FDA-2015-D-1211-0374 | FDA | None FDA-2015-D-1211 | Reference 13 Donor-Testing-and-Risk-2012 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:38Z | 0 | 0 | 09000064859fd845 | |||
| FDA-2015-D-1211-0386 | FDA | None FDA-2015-D-1211 | Reference 25 REV. Custer - Blood DROPS re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:47Z | 0 | 0 | 09000064859fd85b | |||
| FDA-2015-D-1211-0399 | FDA | None FDA-2015-D-1211 | Reference 38_NHS Blood and Transplant_Our Improved Donations Safety Check re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:56Z | 0 | 0 | 09000064859fd93e | |||
| FDA-2015-D-1211-0405 | FDA | None FDA-2015-D-1211 | Reference 44_New Ref 44_HIV incidence in US first-time blood donors during 12-month and 3-month MSM deferral policy periods re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:08:01Z | 0 | 0 | 09000064859fd944 | |||
| FDA-2015-D-1211-0385 | FDA | None FDA-2015-D-1211 | Reference 24 REV. Custer2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:46Z | 0 | 0 | 09000064859fd85a | |||
| FDA-2015-D-1211-0395 | FDA | None FDA-2015-D-1211 | Reference 34 Goldman.MSM Policy changes in Canada.Transfusion.2022 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:53Z | 0 | 0 | 09000064859fd866 | |||
| FDA-2015-D-1211-0400 | FDA | None FDA-2015-D-1211 | Reference 39_FDA_Important Information for Potential Donors of Blood and Blood Products re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:56Z | 0 | 0 | 09000064859fd93f | |||
| FDA-2015-D-1211-0404 | FDA | None FDA-2015-D-1211 | Reference 43 New Reference 43_HIV antiretroviral therapy and prevention use in US blood re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:08:00Z | 0 | 0 | 09000064859fd943 | |||
| FDA-2015-D-1211-0379 | FDA | None FDA-2015-D-1211 | Reference 18_FDA Blood Products Advisory Committee Meeting_September 14-15 2000 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:41Z | 0 | 0 | 09000064859fd84a | |||
| FDA-2015-D-1211-0384 | FDA | None FDA-2015-D-1211 | Reference 23 REV. ACBTSA re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:46Z | 0 | 0 | 09000064859fd859 | |||
| FDA-2015-D-1211-0392 | FDA | None FDA-2015-D-1211 | Refernce 31_HIV Risk Behavior Profiles Among Men Who Have Sex with Men Interested in Donating Blood_ADVANCE Study re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:51Z | 0 | 0 | 09000064859fd863 | |||
| FDA-2015-D-1211-0401 | FDA | None FDA-2015-D-1211 | Reference 40_Initiation of anti-retroviral therapy during acute HIV-1 infection leads to a high rate of nonreactive HIV serology re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:57Z | 0 | 0 | 09000064859fd940 | |||
| FDA-2015-D-1211-0367 | FDA | None FDA-2015-D-1211 | Reference 6 Pubhealthrep00106-0104 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:33Z | 0 | 0 | 09000064859fbfd4 | |||
| FDA-2015-D-1211-0372 | FDA | None FDA-2015-D-1211 | Reference 11 Transfusion-associated_infections re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:36Z | 0 | 0 | 09000064859fd727 | |||
| FDA-2015-D-1211-0380 | FDA | None FDA-2015-D-1211 | Reference 19 FDA Workshop on Behavior-Based Donor Deferral in the NAT Era 2006 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:42Z | 0 | 0 | 09000064859fd84b | |||
| FDA-2015-D-1211-0383 | FDA | None FDA-2015-D-1211 | Reference 22_FDA workshop on Quarantine Release Errors in Blood Establishments_September 2011 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:45Z | 0 | 0 | 09000064859fd858 | |||
| FDA-2015-D-1211-0393 | FDA | None FDA-2015-D-1211 | Reference 32_Caffrey_Removing MSM.Canada.CliniqueTransfusion.2022 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:52Z | 0 | 0 | 09000064859fd864 | |||
| FDA-2015-D-1211-0376 | FDA | None FDA-2015-D-1211 | Reference 15 MMWR_Revised Public Health Service Definition of Persons Who Should Refrain from Donating Blood and Plasma -- United States re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:39Z | 0 | 0 | 09000064859fd847 | |||
| FDA-2015-D-1211-0389 | FDA | None FDA-2015-D-1211 | Reference 28 Lucky2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:49Z | 0 | 0 | 09000064859fd860 | |||
| FDA-2015-D-1211-0398 | FDA | None FDA-2015-D-1211 | Reference 37_Patel et al_Estimating per-act HIV transmission risk re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:55Z | 0 | 0 | 09000064859fd93d | |||
| FDA-2015-D-1211-0406 | FDA | None FDA-2015-D-1211 | Reference 45_New Ref 45_Modeling the Effect of an Individual-Risk Based Deferral Policy re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:08:02Z | 0 | 0 | 09000064859fd945 | |||
| FDA-2015-D-1211-0364 | FDA | None FDA-2015-D-1211 | Reference 3 Dubin_et_al-2013-Transfusion re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:31Z | 0 | 0 | 09000064859fbfd1 | |||
| FDA-2015-D-1211-0365 | FDA | None FDA-2015-D-1211 | Reference 4 Epidemiologic Notes and Reports Pneumocystis carinii Pneumonia among Persons with Hemophilia A re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:31Z | 0 | 0 | 09000064859fbfd2 | |||
| FDA-2015-D-1211-0366 | FDA | None FDA-2015-D-1211 | Reference 5 Epidemiologic Notes and Reports Possible Transfusion-Associated Acquired Immune Deficiency Syndrome (AIDS) -- California re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:32Z | 0 | 0 | 09000064859fbfd3 | |||
| FDA-2015-D-1211-0375 | FDA | None FDA-2015-D-1211 | Reference 14 Klamroth2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:38Z | 0 | 0 | 09000064859fd846 | |||
| FDA-2015-D-1211-0373 | FDA | None FDA-2015-D-1211 | Reference 12 Ward et al_JAMA_256_3_028 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:37Z | 0 | 0 | 09000064859fd844 | |||
| FDA-2015-D-1211-0361 | FDA | None FDA-2015-D-1211 | Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Other | Guidance | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T04:00:00Z | 2024-11-11T21:24:16Z | 1 | 0 | 09000064859fa827 | ||
| FDA-2015-D-1211-0369 | FDA | None FDA-2015-D-1211 | Reference 8 FDA Memorandum Recommendations to decrease the Risk of Tramitting AIDS fro Blood donors re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:34Z | 0 | 0 | 09000064859fc421 | |||
| FDA-2015-D-1211-0377 | FDA | None FDA-2015-D-1211 | Reference 16_FDA Blood Products Advisory Committee Meeting_December 11 1997 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:40Z | 0 | 0 | 09000064859fd848 | |||
| FDA-2015-D-1211-0396 | FDA | None FDA-2015-D-1211 | Reference 35_Advisory Committee on the Safety of Blood Tissues and Organs (SaBTO)_Donor Selection Criteria Report re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:54Z | 0 | 0 | 09000064859fd867 | |||
| FDA-2015-D-1211-0378 | FDA | None FDA-2015-D-1211 | Reference 17_FDA Workshop on Donor Suitability 1998 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:40Z | 0 | 0 | 09000064859fd849 | |||
| FDA-2015-D-1211-0382 | FDA | None FDA-2015-D-1211 | Reference 21 Quarantine-release-errors-white-paper re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:44Z | 0 | 0 | 09000064859fd84d | |||
| FDA-2015-D-1211-0391 | FDA | None FDA-2015-D-1211 | Reference 30_ADVANCE Study re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:50Z | 0 | 0 | 09000064859fd862 | |||
| FDA-2015-D-1211-0381 | FDA | None FDA-2015-D-1211 | Reference 20 HHS Advisory Committee for blood safety and availability mtg 2010 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:43Z | 0 | 0 | 09000064859fd84c | |||
| FDA-2015-D-1211-0388 | FDA | None FDA-2015-D-1211 | Reference 27 Seed2010 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry | Supporting & Related Material | Background Material | 2023-05-12T04:00:00Z | 2023 | 5 | 2023-05-12T20:07:48Z | 0 | 0 | 09000064859fd85f | |||
| FDA-2015-D-1211-0274 | FDA | None FDA-2015-D-1211 | Guidance Documents Related to Coronavirus Disease 2019 (COVID–19) | Notice | General Notice | 2023-03-13T04:00:00Z | 2023 | 3 | 2023-03-13T04:00:00Z | 2023-03-13T14:09:01Z | 2023-05094 | 0 | 0 | 090000648579b2d7 | |
| FDA-2015-D-1211-0151 | FDA | None FDA-2015-D-1211 | Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions To Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2023-01-30T05:00:00Z | 2023 | 1 | 2023-01-30T05:00:00Z | 2023-02-28T14:29:29Z | 2023-01796 | 0 | 0 | 0900006485618fef | |
| FDA-2015-D-1211-0155 | FDA | None FDA-2015-D-1211 | Reference 17_FDA Workshop on Donor Suitability 1998 | Supporting & Related Material | Background Material | 2023-01-30T05:00:00Z | 2023 | 1 | 2023-01-30T14:18:43Z | 0 | 0 | 0900006485618a78 | |||
| FDA-2015-D-1211-0156 | FDA | None FDA-2015-D-1211 | Reference 18_FDA Blood Products Advisory Committee Meeting_September 14-15 2000 | Supporting & Related Material | Background Material | 2023-01-30T05:00:00Z | 2023 | 1 | 2023-01-30T14:19:40Z | 0 | 0 | 0900006485618a79 | |||
| FDA-2015-D-1211-0157 | FDA | None FDA-2015-D-1211 | Reference 19 FDA Workshop on Behavior-Based Donor Deferral in the NAT Era 2006 | Supporting & Related Material | Background Material | 2023-01-30T05:00:00Z | 2023 | 1 | 2023-01-30T14:20:46Z | 0 | 0 | 0900006485618a6b | |||
| FDA-2015-D-1211-0158 | FDA | None FDA-2015-D-1211 | Reference 22_FDA workshop on Quarantine Release Errors in Blood Establishments_September 2011 | Supporting & Related Material | Background Material | 2023-01-30T05:00:00Z | 2023 | 1 | 2023-01-30T14:21:52Z | 0 | 0 | 0900006485618a6c | |||
| FDA-2015-D-1211-0152 | FDA | None FDA-2015-D-1211 | Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions To Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry; Availability | Other | Guidance | 2023-01-30T05:00:00Z | 2023 | 1 | 2023-01-30T05:00:00Z | 2023-04-01T03:59:59Z | 2025-02-05T02:00:53Z | 1 | 0 | 0900006485618a68 | |
| FDA-2015-D-1211-0159 | FDA | None FDA-2015-D-1211 | New Reference 30_ADVANCE Study | Supporting & Related Material | Background Material | 2023-01-30T05:00:00Z | 2023 | 1 | 2023-01-30T14:22:43Z | 0 | 0 | 0900006485618a6d | |||
| FDA-2015-D-1211-0160 | FDA | None FDA-2015-D-1211 | New Ref 32- O Brien - Donor screening question alternatives to men who have sex with men time deferral Potential (1) | Supporting & Related Material | Background Material | 2023-01-30T05:00:00Z | 2023 | 1 | 2023-01-30T14:24:06Z | 0 | 0 | 0900006485618a6e | |||
| FDA-2015-D-1211-0154 | FDA | None FDA-2015-D-1211 | Reference 16_FDA Blood Products Advisory Committee Meeting_December 11 1997 | Supporting & Related Material | Background Material | 2023-01-30T05:00:00Z | 2023 | 1 | 2023-01-30T14:17:37Z | 0 | 0 | 0900006485618a77 | |||
| FDA-2015-D-1211-0153 | FDA | None FDA-2015-D-1211 | New Ref 15 MMWR_Revised Public Health Service Definition of Persons Who Should Refrain from Donating Blood and Plasma -- United States | Supporting & Related Material | Background Material | 2023-01-30T05:00:00Z | 2023 | 1 | 2023-01-30T14:17:49Z | 0 | 0 | 0900006485618a6a | |||
| FDA-2015-D-1211-0161 | FDA | None FDA-2015-D-1211 | New Ref 37_NHS Blood and Transplant_Our Improved Donations Safety Check | Supporting & Related Material | Background Material | 2023-01-30T05:00:00Z | 2023 | 1 | 2023-01-30T14:24:58Z | 0 | 0 | 0900006485618a7c |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;